Ascendis Pharma A/S (ASND) closed at $239.77 on Sep 15, 2026, down 9.5% on the day. The stock is down 3.5% over the past month, up 7.4% over three months, up 12.4% year to date and up 22.6% over the past year. It trades 15.0% below its 52-week high of $282.15 and 27.5% above its 52-week low of $188.07. The close sits below its 50-day moving average ($256.75) and above its 200-day moving average ($233.96).
Yes — the Sep 15, 2026 close of $239.77 is 2.5% above the 200-day average of $233.96.
ASND closed 15.0% below its 52-week high of $282.15.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
